Geoffrey Wu

Geoffrey Wu, PhD*, is a regulatory review officer, geoffrey.wu@fda.hhs.gov.

Articles by Geoffrey Wu

Regulatory Considerations for Controlled Correspondence Related to Generic Drug Chemistry

ByGeoffrey Wu,Lane Christensen,Thomas O’Connor,Frank Holcombe Jr.,Susan Rosencrance,Andre Raw,Kristina Adams,Xiaochuan Yang,Min Li

September 1st 2015

An analysis of controlled correspondence between generic-drug manufacturers and FDA reveals patterns in questions about specific drug chemistry topics and the response to information provided in FDA guidance documents.

Latest Updated Articles

Regulatory Considerations for Controlled Correspondence Related to Generic Drug Chemistry
Published: September 1st 2015 | Updated:

Geoffrey Wu

Articles by Geoffrey Wu

Regulatory Considerations for Controlled Correspondence Related to Generic Drug Chemistry

Latest Updated Articles

Trending on Pharmaceutical Technology

How Therapeutic and Analytical Advancements Help Drug Substance Testing Evolve

Shifting from Trial-and-Error to Rational Design Drives Efficiency in Pharmaceutical Formulation